Daiichi Sankyo's Enhertu Shows First-Line Success in HER2 Mutant NSCLC — Daiichi Sankyo Company, Limited

Event summary

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) as a first-line treatment for HER2 mutant advanced non-small cell lung cancer (NSCLC) in the DESTINY-Lung04 phase 3 trial.
The trial compared Enhertu to the global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab).
The safety profile of Enhertu was consistent with its known profile with no new safety concerns identified.
The DESTINY-Lung04 data will be presented at an upcoming medical meeting and shared with global regulatory authorities.

The big picture

Daiichi Sankyo's Enhertu continues to expand its clinical utility in oncology, now showing promise in the first-line treatment of HER2 mutant NSCLC. This success builds on its established role in second-line treatment and other cancer indications, positioning Enhertu as a key player in the antibody-drug conjugate (ADC) market. The collaboration with AstraZeneca further strengthens its development and commercialization strategy.

What we're watching

Regulatory Approval: Whether global regulatory authorities will approve Enhertu for first-line treatment of HER2 mutant NSCLC based on the DESTINY-Lung04 data.
Market Penetration: The pace at which Enhertu can gain market share in the first-line treatment setting for HER2 mutant NSCLC.
Competitive Dynamics: How other HER2-targeted therapies will respond to Enhertu's success in this indication.